国际标准期刊号: 2165-7904

肥胖与减肥治疗杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 打开 J 门
  • Genamics 期刊搜索
  • 国际农业与生物科学中心 (CABI)
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • SWB 在线目录
  • CABI 全文
  • 出租车直达
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • 布里斯托大学
  • 出版医学
  • ICMJE
分享此页面

抽象的

Effects of Fish Oil on Cytokines, Glycemic Control, Blood Pressure, and Serum Lipids in Patients with Type 2 Diabetes Mellitus

Reza Rastmanesh, Afrooz Javidi, Fourough A Taleban, Masood Kimaigar and Yadollah Mehrabi

Objective: We examined the ability of dietary fish oil to suppress markers of inflammation and consequent effect(s) on serum fasting glycemia, lipids, and blood pressure in patients with T2DM. Design: Correlations between serum fasting interleukin-6, Interleukin-1β (IL-1β), TNF-α (TNF-α), C-reactive Protein (CRP), and sialic acid, with indices of glycemia, insulin, and lipids were determined in 26 patients with T2DM at baseline, 4 weeks and 8 weeks after supplementation with fish oil (3 g/d) to analyse possible correlations between markers of inflammation and indices of glycemia. Results: There were no significant correlations between markers of inflammation with indices of glycemia at baseline, 4 weeks and 8 weeks after fish oils supplementation. Serum CRP concentrations were negatively correlated with fasting serum LDL, and with Cholesterol (r=-0.424, P<0.04; r=- 0.447, P<0.03, respectively). Fasting IL-1 β concentrations were positively correlated with fasting LDL, and with cholesterol at week 4 (r=0.482, P<0.02; r=0.469, P<0.02, respectively). There were no significant correlations between serum lipids with markers of inflammation at the end of intervention. There were no significant changes in serum fasting insulin, and glucose concentrations at the end of the intervention. Conclusions: A moderate dose of fish oil did not lead to deleterious effects on glycemic control in patients with T2DM, with preserved triacyglycerol-lowering capacities.